High expression of CXC chemokine receptor 6 associates with poor prognosis in patients with clear cell renal cell carcinoma
Urologic Oncology: Seminars and Original Investigations Sep 20, 2017
Chang Y, et al. - An inquiry was set up of the prognostic value of CXCR6 expression in patients with clear cell renal cell carcinoma (ccRCC) following surgery. The findings disclosed that the expression of CXCR6 in tumor tissue could serve as a potential prognostic biomarker to refine clinical prognosis prediction combined with traditional clinical and pathological analysis for the study cohort.
- 239 patients with ccRCC who underwent nephrectomy and had paraffin tissue available at a single center were recruited for this study.
- A scrutiny was performed of the CXCR6 expression in tumor tissue via immunohistochemistry.
- In addition, its correlations with overall survival (OS) and recurrence-free survival (RFS) were evaluated.
- 47.3% tumors were regarded as high expression of CXCR6.
- These exhibited notable link with the male sex (P = 0.003) and high Fuhrman grade (P<0.001).
- A high expression of CXCR6 indicated a reduced OS (P<0.001) and RFS (P = 0.007).
- Multivariate analysis disclosed that CXCR6 expression was an independent prognostic factor of OS (hazard ratio = 2.604; 95% CI: 1.338-5.068; P = 0.005) and RFS (hazard ratio = 1.957; 95% CI: 1.065-3.595; P = 0.031).
- It was determined that CXCR6 expression could differentiate survival risks among patients with high-risk disease.
- A nomogram integrating CXCR6 expression and traditional clinical and pathologic features was established and predicted postsurgical recurrence-risk well at 3- and 5-year.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins